BRIEF—UK's Medicines Discovery Catapult in new AMR project

The Medicines Discovery Catapult, the UK government-backed body that seeks to speed drug discovery and development, has launched a project with Antruk Enterprises to find new approaches to tackling anti-microbial resistance (AMR).

Antruk Enterprises is a wholly owned subsidiary of Antibiotic Research UK, a charity dedicated to tackling AMR.

It is the inaugural project at the new Medicines Discovery Catapult Facility at the University of Warwick.

In collaboration with Chris Dowson, of the university’s Infectious Disease Research Group, researchers will combine antibiotics to combat resistance and identify new resistance breakers, translating research into new solutions for patients.